$97.78
4.47% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US74276L1052
Symbol
PRCT
Sector

PROCEPT BioRobotics Stock price

$97.78
+29.01 42.18% 1M
+30.88 46.16% 6M
+55.87 133.31% YTD
+63.11 182.03% 1Y
+60.70 163.70% 3Y
+55.84 133.14% 5Y
+55.84 133.14% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+4.18 4.47%
ISIN
US74276L1052
Symbol
PRCT
Sector

Key metrics

Market capitalization $5.32b
Enterprise Value $5.20b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 26.03
P/S ratio (TTM) P/S ratio 26.61
P/B ratio (TTM) P/B ratio 21.14
Revenue growth (TTM) Revenue growth 71.71%
Revenue (TTM) Revenue $199.84m
EBIT (operating result TTM) EBIT $-106.46m
Free Cash Flow (TTM) Free Cash Flow $-103.57m
Cash position $196.76m
EPS (TTM) EPS $-1.95
P/E forward negative
P/S forward 23.84
EV/Sales forward 23.32
Short interest 14.74%
Show more

Is PROCEPT BioRobotics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

PROCEPT BioRobotics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a PROCEPT BioRobotics forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a PROCEPT BioRobotics forecast:

Buy
78%
Hold
22%

Financial data from PROCEPT BioRobotics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
200 200
72% 72%
100%
- Direct Costs 90 90
54% 54%
45%
110 110
90% 90%
55%
- Selling and Administrative Expenses 154 154
32% 32%
77%
- Research and Development Expense 57 57
39% 39%
28%
-101 -101
1% 1%
-51%
- Depreciation and Amortization 5.10 5.10
19% 19%
3%
EBIT (Operating Income) EBIT -106 -106
2% 2%
-53%
Net Profit -100 -100
6% 6%
-50%

In millions USD.

Don't miss a Thing! We will send you all news about PROCEPT BioRobotics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PROCEPT BioRobotics Stock News

Positive
Seeking Alpha
about 2 hours ago
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage.
Neutral
GlobeNewsWire
27 days ago
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 p...
Neutral
GlobeNewsWire
29 days ago
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also ...
More PROCEPT BioRobotics News

Company Profile

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Head office United States
CEO Reza Zadno
Employees 626
Founded 2007
Website www.procept-biorobotics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today